Literature DB >> 11694613

In vivo comparison of the bioavailability of (+)-catechin, (-)-epicatechin and their mixture in orally administered rats.

S Baba1, N Osakabe, M Natsume, Y Muto, T Takizawa, J Terao.   

Abstract

We compared levels of (+)-catechin, (-)-epicatechin, and their metabolites in rat plasma and urine after oral administration. Rats were divided into four groups and given (+)-catechin (CA group), (-)-epicatechin (EC group), a mixture of the two (MIX group) or deionized water. Blood samples were collected before administration and at designated time intervals thereafter. Urine samples were collected 0-24 h postadministration. (+)-Catechin, (-)-epicatechin and their metabolites in plasma and urine were analyzed by HPLC-mass spectrometry after treatment with beta-glucuronidase and/or sulfatase. After administration, absorbed (+)-catechin and (-)-epicatechin were mainly present in plasma as metabolites, such as nonmethylated or 3'-O-methylated conjugates. In the CA and MIX groups, the primary metabolite of (+)-catechin in plasma was glucuronide in the nonmethylated form. In the EC and MIX groups, in contrast, the primary metabolites of (-)-epicatechin in plasma were glucuronide and sulfoglucuronide in nonmethylated forms, and sulfate in the 3'-O-methylated forms. Urinary excretion of the total amount of (-)-epicatechin metabolites in the EC group was significantly higher than the amount of (+)-catechin metabolites in the CA group. The sum of (+)-catechin metabolites in the urine was significantly lower in the MIX group than in the CA group, and the sum of (-)-epicatechin metabolites in the MIX group was also significantly lower than in the EC group. These results suggest that the bioavailability of (-)-epicatechin is higher than that of (+)-catechin in rats, and that, in combination, (+)-catechin and (-)-epicatechin might be absorbed competitively in the gastrointestinal tract of rats.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11694613     DOI: 10.1093/jn/131.11.2885

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  34 in total

1.  Enzymatic synthesis of substituted epicatechins for bioactivity studies in neurological disorders.

Authors:  Jack W Blount; Mario Ferruzzi; Dan Raftery; Giulio M Pasinetti; Richard A Dixon
Journal:  Biochem Biophys Res Commun       Date:  2011-12-07       Impact factor: 3.575

2.  Chocolate matrix factors modulate the pharmacokinetic behavior of cocoa flavan-3-ol phase II metabolites following oral consumption by Sprague-Dawley rats.

Authors:  Andrew P Neilson; Teryn N Sapper; Elsa M Janle; Ralf Rudolph; Nathan V Matusheski; Mario G Ferruzzi
Journal:  J Agric Food Chem       Date:  2010-06-09       Impact factor: 5.279

3.  Cerebroprotection of flavanol (-)-epicatechin after traumatic brain injury via Nrf2-dependent and -independent pathways.

Authors:  Tian Cheng; Wenzhu Wang; Qian Li; Xiaoning Han; Jing Xing; Cunfang Qi; Xi Lan; Jieru Wan; Alexa Potts; Fangxia Guan; Jian Wang
Journal:  Free Radic Biol Med       Date:  2015-12-25       Impact factor: 7.376

4.  Comparative effects of dietary flavanols on antioxidant defences and their response to oxidant-induced stress on Caco2 cells.

Authors:  Ildefonso Rodríguez-Ramiro; María Angeles Martín; Sonia Ramos; Laura Bravo; Luis Goya
Journal:  Eur J Nutr       Date:  2010-11-03       Impact factor: 5.614

5.  Oral administration of the flavanol (-)-epicatechin bolsters endogenous protection against focal ischemia through the Nrf2 cytoprotective pathway.

Authors:  Christopher C Leonardo; Megha Agrawal; Nilendra Singh; J Russell Moore; Shyam Biswal; Sylvain Doré
Journal:  Eur J Neurosci       Date:  2013-09-23       Impact factor: 3.386

6.  Pharmacokinetics of TJ-8117(Onpi-to), a drug for renal failure (II): effects of food, repeated administration and renal failure to plasma concentration of [3H]-(-)epicatechin 3-O-gallate in rats.

Authors:  Yukiho Takizawa; Toshimi Morita; Naoki Fujitsuka; Akiko Kido; Shouichirou Shindou; Hiroki Tomisawa; Yoshio Kase; Shuichi Takeda; Masaki Aburada; Keńtchi Miyamoto
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jul-Sep       Impact factor: 2.441

7.  Plasma pharmacokinetics of catechin metabolite 4'-O-Me-EGC in healthy humans.

Authors:  Mathieu Renouf; Karine Redeuil; Karin Longet; Cynthia Marmet; Fabiola Dionisi; Martin Kussmann; Gary Williamson; Kornél Nagy
Journal:  Eur J Nutr       Date:  2011-01-07       Impact factor: 5.614

Review 8.  Biological activities of polyphenols from grapes.

Authors:  En-Qin Xia; Gui-Fang Deng; Ya-Jun Guo; Hua-Bin Li
Journal:  Int J Mol Sci       Date:  2010-02-04       Impact factor: 5.923

9.  Absorptive interactions of concurrent oral administration of (+)-catechin and puerarin in rats and the underlying mechanisms.

Authors:  Hui-fang Su; Qing Lin; Xin-yi Wang; Yao Fu; Tao Gong; Xun Sun; Zhi-rong Zhang
Journal:  Acta Pharmacol Sin       Date:  2016-03-14       Impact factor: 6.150

10.  Bioavailability of gallic acid and catechins from grape seed polyphenol extract is improved by repeated dosing in rats: implications for treatment in Alzheimer's disease.

Authors:  Mario G Ferruzzi; Jessica K Lobo; Elsa M Janle; Bruce Cooper; James E Simon; Qing-Li Wu; Cara Welch; Lap Ho; Connie Weaver; Giulio M Pasinetti
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.